Key Outcomes:
- XellSmart (XS411, Parkinson’s): P1 (n=9) showed >30-point average improvement in OFF-state MDS-UPDRS Part III and >5 hr/day of added ON time without troublesome dyskinesia at 6 months. There were no DLTs, SAEs, tumors, or graft-induced dyskinesia. Enrollment is complete for the 30-patient P2 in China.
- Muna (MNA-001, Alzheimer’s): P1 showed favorable safety, strong CSF exposure and dose-dependent target engagement. Exploratory CSF markers in elderly participants shifted toward younger-volunteer levels. P2 is planned for early 2027.
- ArriVent (ARR-217, CDH17 ADC, CRC): At 6 mg/kg Q3W, ORR was 44.8% and DCR 93.1%. Grade ≥3 TRAEs were 30.1% across all doses and 20.4% at 6 mg/kg, with no Grade 5 events or ILD. It advances to P1b dose optimization, with data in 2027.
- Zhimeng (CB03-154, ALS): Enrollment of 255 patients in the pivotal P2/3 is complete. The primary endpoint is ALSFRS-R change at Wk 39, and topline results are expected in 3Q27, followed by a conditional approval filing with China CDE.
- Estuary (ADPKD gene therapy): Launched with $103M ($93M Series A led by RA Capital plus a $10M seed). EST-201 is expected to enter the clinic in 2027 and EST-101 in 2028.
- Vivacta Bio / Grit Bio (GT801, AIHA): FDA granted ODD to the in vivo CAR-T. Both treated AIHA patients achieved complete responses, with B-cell depletion and improved hemoglobin.
- Rznomics (RZ-001, glioma): EC granted Orphan Designation, offering up to 10 years of market exclusivity. It also holds FDA ODD, Fast Track and RMAT designations in HCC and GBM.
- INOVIO (VOCERYQ, RRP): FDA accelerated approval based on P1/2 data. 27% (7/26) had a complete response with no surgery at 12 months, and no surgeries were needed during the dosing window. Commercial launch is planned for Q1 2027.
- Telix / Ekalia (astatine-211): Partnership to establish U.S. At-211 production with a cyclotron in Trevose, PA, securing priority isotope supply for Telix’s alpha-therapy pipeline, including TLX102-Tx.
- Roche / Zymeworks (ZW209, DLL3 TCE): Deal worth up to $813M, including $55M upfront, $40M at P1b initiation and up to $718M in milestones, plus tiered royalties.
- Genmab / Incyte (mCRC, KRAS G12D): Clinical collaboration for a P1/2 study of petosemtamab plus INCB161734 and chemotherapy as first-line treatment. Genmab runs the study, and Incyte co-funds it and supplies the drug.
- Teva / BioXcel (BXCL501): Teva acquired the assets for $57.5M upfront and up to $67.5M in contingent payments. The sNDA has an FDA action date of Nov 14, 2026, and it could be the first approved at-home agitation treatment.
- Astellas / Audax (DAX-044, IL-12): Option and license deal worth up to $1.34B, including $285M in upfront and option payments. Audax funds development into P1, expected in 2027.
- ABM Respiratory Care: $20M growth capital commitment from Trinity Capital to expand commercialization of the BiWaze platform and the Arc Connect digital health platform.
- Adsilico (Virtual Chimera): Raised £10M ($13M) Series A to expand virtual heart models and neurovascular simulations, growing the team from 14 to 34.
- Dren Bio (dibotatug): Closed an oversubscribed $350M financing to support late-stage development, regulatory submissions, and planned commercialization.
October 18, 2026
XellSmart Reports P1 Results for XS411 and Completes P2 Enrollment in Parkinson’s Disease
XellSmart presented P1 results for XS411, an off-the-shelf, iPSC-derived dopaminergic cell therapy for Parkinson’s disease, at the International Congress of Parkinson’s Disease and Movement Disorders (MDS). In the nine-patient, open-label study, patients showed an average improvement of over 30 points in OFF-state MDS-UPDRS Part III motor scores and gained >5hr of daily ON time without troublesome dyskinesia at 6mos. No DLTs, SAEs, tumor formation, or graft-induced dyskinesia were reported; ¹⁸F-DOPA PET imaging also indicated increased activity at transplant sites. The company completed enrolment of all 30 participants in its randomized P2 study in China; transplantation in the treatment group is complete, and follow-up is ongoing. XS411 has received FDA’s FTD and support under China’s National Major Innovative Drug Program, with P2 results expected to guide P3 planning.
Source: PR Newswire PR Oct 18, 2026
October 21, 2026
Muna Therapeutics Reports Positive P1 Results for Oral TREM2 Modulator MNA-001 in Alzheimer’s Disease
Muna Therapeutics reported positive P1 results for MNA-001, an oral small-molecule TREM2 modulator being developed for early Alzheimer’s disease. The randomized, double-blind, pbo-controlled study in younger and elderly volunteers demonstrated favourable safety and tolerability, with no SAEs or discontinuations due to AEs. MNA-001 achieved strong cerebrospinal fluid (CSF) exposure, dose-dependent target engagement, and similar pharmacokinetics across age groups. Exploratory CSF analyses showed that repeated dosing shifted age-associated markers of microglial activity, innate immune activation, and neuronal stress in elderly participants toward levels observed in younger volunteers, providing preliminary evidence of downstream biological activity. Muna plans to initiate a P2 study in early 2027 to evaluate cognitive outcomes and disease-progression biomarkers.
Source: PR Newswire PR Oct 21, 2026
October 25, 2026
ArriVent Reports Positive Initial P1 Results for CDH17-Targeted ADC ARR-217 in Gastrointestinal Cancers
ArriVent BioPharma reported initial P1 results for ARR-217 (MRG007), a CDH17-targeted ADC developed in partnership with Lepu Biopharma, at the 2026 ESMO Congress. In heavily pretreated colorectal cancer (CRC) patients.
ARR-217 (CDH17-targeted ADC) P1 Results, ESMO 2026
Efficacy Result:
Safety Result:
ARR-217 has advanced to P1b dose optimization at 5 and 6 mg/kg Q3W, with further data expected in 2027.
Source: ArriVent BioPharma PR Oct 25, 2026
October 31, 2026
Zhimeng Biopharma Completes Enrollment of Pivotal P2/3 Trial of CB03-154 in ALS
Shanghai Zhimeng Biopharma reported it has completed enrollment of 255 patients in the pivotal P2/3 study of CB03-154, its next-generation, selective KCNQ2/3 potassium channel opener, for ALS in China. The study is run at 15 clinical centers in Mainland China, led by Prof. Fan Dongsheng (Peking University Third Hospital). The primary endpoint is change from baseline in ALSFRS-R score at Wk 39. CB03-154 received China CDE approval to start the P2/3 in Jul 2025 and FDA Orphan Drug Designation in Oct 2023. If topline results are positive in 3Q27, Zhimeng plans to file with the China CDE for conditional approval. CB03-154 is also in P2 for focal epilepsy (China and Australia) and received CDE approval in June 2026 to start a P2 in MDD. In preclinical studies, the compound showed neuroprotective effects on motor neurons by restoring the excitation/inhibition balance.
Source: PR Newswire PR Oct 31, 2026
October 16, 2026
Estuary Biotherapeutics Launches with $103M to Develop Targeted Gene Therapies for Kidney Disease
Estuary Biotherapeutics launched with $103M in total financing, comprising a $93M Series A led by RA Capital Management and a previously raised $10M seed round. The funding will advance two investigational adeno-associated virus (AAV)-based gene therapies for autosomal dominant polycystic kidney disease (ADPKD), an inherited disorder affecting more than eight million people worldwide. EST-201, designed to deliver a functional PKD2 gene, is expected to enter clinical trials in 2027, while EST-101, which delivers a functional region of the polycystin-1 protein for patients with PKD1 mutations, is expected to enter trials in 2028. Both programs use localized, kidney-directed delivery designed to address the underlying genetic cause of ADPKD, with the potential to halt or reverse disease progression. The financing will support clinical POC and expansion of Estuary’s kidney-targeted genetic medicine platform.
Source: Business Wire PR Oct 16, 2026
October 17, 2026
Vivacta Bio and Grit Bio Secure FDA’s ODD for GT801 in Autoimmune Hemolytic Anemia
Vivacta Bio and Grit Bio reported that the FDA granted ODD to GT801, an investigational in vivo CAR-T therapy, for autoimmune hemolytic anemia (AIHA). GT801 uses mRNA delivered through T-cell-targeted lipid nanoparticles (LNPs) to generate CD19-directed CAR-T cells directly inside the patient, targeting B cells responsible for antibody-mediated red blood cell destruction. Preliminary clinical data presented at the ASGCT’26 which showed complete responses in both AIHA patients treated: one achieved a response by wk 4 that persisted through 3rd mos., while the other achieved a response by wk 10. Both patients also showed B-cell depletion and improvements in hemoglobin and other disease-associated laboratory markers. The designation may provide eligibility for clinical-trial tax credits, FDA application-fee exemptions and seven years of market exclusivity following approval, subject to applicable requirements. GT801’s in vivo approach is designed to eliminate the need for cell collection, ex vivo manufacturing and lymphodepletion required by conventional CAR-T therapies.
Source: PR Newswire PR Oct 17, 2026
October 22, 2026
Rznomics Secures European Commission Orphan Drug Designation for RZ-001 in Glioma
Rznomics reported that the EC granted Orphan Medicinal Product Designation to taspitimagene advec (RZ-001), its RNA-editing gene therapy for glioma, following a positive recommendation from the EMA’s Committee for Orphan Medicinal Products on Sep 28, 2026. The designation provides potential development benefits, including regulatory support, reduced fees, and up to 10 years of market exclusivity following approval, subject to applicable requirements. In the U.S., RZ-001 has received FDA Orphan Drug and Fast Track designations for hepatocellular carcinoma (HCC) and glioblastoma (GBM), as well as Regenerative Medicine Advanced Therapy (RMAT) designation for HCC in May 2026. Rznomics plans to pursue global partnerships and expand RZ-001 development into additional solid tumors beyond HCC and GBM.
Source: Rznomics PR Oct 22, 2026
October 30, 2026
INOVIO Receives FDA Accelerated Approval for VOCERYQ to Reduce Surgery in Adults with Recurrent Respiratory Papillomatosis
INOVIO Pharmaceuticals received FDA accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd; formerly INO-3107), a plasmid DNA-based immunotherapy designed to target HPV-6 and HPV-11, the primary causes of recurrent respiratory papillomatosis (RRP). Approval was supported by the P1/2 RRP-001 study.
Result:
The therapy is administered intramuscularly using INOVIO’s CELLECTRA 5PSP delivery device. Continued approval may depend on confirmatory studies to verify clinical benefit; INOVIO plans to submit a draft study protocol by the end of 2026 and finalize it by mid-2027. The company expects VOCERYQ to become available for ordering and shipping in approximately 60 days, with full commercial launch planned for Q1 2027.
Source: INOVIO PR Oct 30, 2026
October 19, 2026
Telix and Ekalia Partner to Establish U.S. Astatine-211 Production
Telix Pharmaceuticals and Ekalia (a JV between IBA & Framatome), reported a collaboration to establish scalable U.S. production of astatine-211 (²¹¹At), a scarce alpha-emitting radioisotope for investigational targeted alpha cancer therapies. The first IBA alpha-beam cyclotron is planned for installation at Telix’s RLS Radiopharmacies site in Trevose, Pennsylvania, with potential expansion to additional sites. The collaboration provides Telix with dedicated, long-term priority access to astatine-211 for its alpha-therapy pipeline, including TLX102-Tx for glioblastoma and leptomeningeal disease, while also supporting 3rd party academic and industry research. The initiative aims to address limited isotope supply and strengthen U.S. production capacity.
Source: GlobeNewswire PR Oct 19, 2026
October 23, 2026
Roche Licenses Zymeworks’ Trispecific T-Cell Engager ZW209 in Deal Worth Up to $813M
Roche entered an exclusive global licensing and collaboration agreement with Zymeworks to develop and commercialize ZW209, a preclinical trispecific T-cell engager targeting DLL3 on tumor cells and CD3/CD28 on T cells for lung cancer and other DLL3-expressing tumors. Zymeworks will receive $55M upfront, an additional $40M upon initiation of P1b, and up to $718M in development, commercial, and sales milestones, plus tiered royalties ranging from high-single-digit to mid-teen percentages on future net sales. Zymeworks will conduct the P1a monotherapy study, funded by Roche, assessing safety, tolerability, pharmacokinetics, and preliminary efficacy in advanced solid tumors, including small-cell lung cancer and DLL3-expressing neuroendocrine tumors. Roche will lead subsequent global development, regulatory activities, and commercialization. The agreement remains subject to applicable antitrust waiting-period requirements and other customary closing conditions.
Source: BioSpace PR Oct 23, 2026
October 24, 2026
Genmab and Incyte Collaborate on P1/2 Study of Combination Therapy for KRAS G12D-Mutated Colorectal Cancer
Genmab and Incyte announced a clinical Study collaboration to evaluate petosemtamab (GEN1158), Genmab’s investigational EGFR/LGR5-targeting bispecific antibody, combined with INCB161734, Incyte’s oral KRAS G12D inhibitor, and standard-of-care chemotherapy as a first-line treatment for KRAS G12D-mutated metastatic colorectal cancer (mCRC). Genmab will conduct the P1/2 study, while Incyte will co-fund the Study and supply INCB161734. The combination aims to target complementary cancer pathways in a patient population with significant unmet medical need. KRAS mutations occur in approximately 40% of colorectal cancers, with G12D being the most common subtype.
Source: Genmab PR Oct 24, 2026
October 27, 2026
Teva Acquires Worldwide Rights to BXCL501 and Other Neuroscience Assets from BioXcel Therapeutics for Up to $125M
Teva Pharmaceuticals completed the acquisition of neuroscience assets from BioXcel Therapeutics through a court-supervised sale process under Section 363 of the U.S. Bankruptcy Code. The acquired assets include worldwide rights to BXCL501, an investigational dexmedetomidine sublingual film under FDA review for at-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults, and IGALMI, an FDA-approved formulation for hospital use. Teva paid $57.5M upfront, with up to $67.5M in contingent payments linked to regulatory approval timing and sales milestones. BXCL501’s sNDA has an FDA target action date of Nov 14, 2026. If approved, it could become the first FDA-approved at-home treatment for acute agitation in these patient populations. The transaction covers the assets, not BioXcel Therapeutics as a company.
Source: GlobeNewswire PR Oct 27, 2026
October 28, 2026
Astellas and Audax Biosciences Enter Option and License Agreement for DAX-044, an IL-12 Antibody-Cytokine Fusion for Immuno-Oncology
Astellas and Audax Biosciences (Australia) entered into an exclusive option and license agreement for DAX-044, Audax’s lead IO AVIKINE candidate. Astellas gets an option to obtain a worldwide license to develop, manufacture, and commercialize DAX-044. Audax will fund and continue development into a P1 study, expected to start in 2027, and has the option to co-fund and co-promote in Australia and New Zealand. DAX-044 is an investigational, immune-targeted IL-12 antibody-cytokine fusion designed to concentrate IL-12 activity in the tumor microenvironment while limiting the systemic toxicity that has historically constrained IL-12 therapies. Preclinical data suggest a potentially best-in-class therapeutic index for an IL-12 agent, and the program is in IND/CTN-enabling development. Audax will receive $285M in upfront and option exercise payments, plus up to $1.05B in development and commercial milestones and tiered double-digit royalties on worldwide net sales if approved. Total potential value is up to $1.34B, excluding royalties. Option exercise is subject to customary conditions, including antitrust clearances.
Source: Astellas PR Oct 28, 2026
October 20, 2026
ABM Respiratory Care Secures $20M Growth Capital Commitment from Trinity Capital
ABM Respiratory Care secured a $20M growth capital commitment from Trinity Capital to accelerate commercial expansion, strengthen its presence in existing and new markets, and support product innovation, clinical research, and connected respiratory care technologies. The financing will support its BiWaze platform, comprising two FDA-cleared systems: BiWaze Clear for airway clearance and lung expansion, and BiWaze Cough to help patients with ineffective coughs clear secretions. ABM is also advancing its Arc Connect digital health platform for patient engagement, therapy tracking, and improved visibility into treatment utilization. The financing provides additional capital and operating flexibility to expand access to its respiratory care technologies across hospital and home-care settings.
Source: PR Newswire PR Oct 20, 2026
October 26, 2026
Adsilico Raises £10M ($13M) in Series A Funding to Expand AI-Powered Virtual Patient Simulation
Adsilico, a University of Leeds spinout, raised £10M ($13M) in Series A funding led by PXN Ventures, with participation from existing investors Northern Gritstone and Parkwalk. The company develops Virtual Chimera, an AI-powered platform that combines generative AI and physics-based simulations to create virtual hearts and blood vessels from anonymized clinical scans, enabling medical device manufacturers to assess implant performance across diverse patient populations before clinical trials. The funding will support the expansion of its virtual heart models, development of neurovascular device simulations including flow diverters for brain aneurysms and team growth from 14 to 34 employees. The technology aims to identify potential device-performance issues earlier, improve clinical Study planning, and potentially reduce reliance on animal testing.
Source: FinSMEs PR Oct 26, 2026
October 29, 2026
Dren Bio Raises $350M to Advance Dibotatug Toward Commercialization and Expand Its Pipeline
Dren Bio reported the closing of an oversubscribed $350M private financing, co-led by Juvia Group and Lightspeed Venture Partners, with participation from new and existing healthcare investors, including Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, OrbiMed, 8VC and SR One. The proceeds will support late-stage clinical development, regulatory submissions and planned commercialization of dibotatug (DR-01), an investigational, first-in-class anti-CD94 monoclonal antibody designed to selectively deplete pathogenic cytotoxic cells while preserving the broader immune system. Dibotatug is being evaluated in patients with cytotoxic T-cell lymphoma and large granular lymphocytic leukemia, with further development planned across additional hematologic and autoimmune indications. The financing will also accelerate Dren Bio’s broader oncology and autoimmune pipeline, including programs using its proprietary Targeted Myeloid Engager and Phagocytosis Platform.
Source: Business Wire PR Oct 29, 2026
Thank you for your attention! For any queries, contact us at bd@octavusconsulting.com
Babli Singh is a Senior Analyst with strong analytical skills and a deep understanding of the biopharmaceutical and healthcare industries. She specializes in monitoring emerging trends and distilling complex information into concise, insightful summaries that deliver clear value and actionable intelligence for a global professional audience.
